Marksans Pharma Limited has announced the incorporation of two new wholly-owned subsidiaries. Marksans Pharma (Europe) Limited is established in Ireland, while Marksans (Canada) Inc. is incorporated in Canada. These strategic moves aim to expand the company’s global footprint in the pharmaceutical sector and support its long-term growth strategy.
Expansion Through New Subsidiaries
Marksans Pharma Limited has officially announced the establishment of two new wholly-owned subsidiaries, signaling a strategic move to broaden its international operations. The two new entities are:
- Marksans Pharma (Europe) Limited in Ireland
- Marksans (Canada) Inc. in Canada
Strategic Rationale
The incorporation of Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada is intended to further support Marksans Pharma’s business activities in the global pharmaceutical market. Each subsidiary is designed to operate within the pharmaceutical sector, aligning with the parent company’s core business.
Both entities are newly incorporated, which means there is no prior operating history or turnover to report. The formation of these subsidiaries represents a prospective expansion of Marksans Pharma’s market presence and operational capabilities.
Source: BSE
